A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors Meeting Abstract


Authors: Cranmer, L.; Razak, A. A.; Ratan, R.; Choy, E.; George, S.; Liebner, D.; Stenehjem, D.; Gounder, M.
Abstract Title: A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors
Meeting Title: 113th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title: Cancer Research
Volume: 82
Issue: 12 Suppl.
Meeting Dates: 2022 Apr 8-13
Meeting Location: New Orleans, LA
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2022-06-15
Language: English
ACCESSION: WOS:000892509502105
PROVIDER: wos
DOI: 10.1158/1538-7445.AM2022-CT185
Notes: Meeting Abstract: CT185 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mrinal M Gounder
    229 Gounder